Study #2021-0319
A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
JNJ-75276617
Description
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-75276617 in Part 1 (Dose Escalation) and to determine safety and tolerability at the RP2D(s) in Part 2 (Dose Expansion).
Information and next steps
Disease:
Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study phase:
I
Physician name:
Elias Jabbour
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.